192 related articles for article (PubMed ID: 37626430)
1. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Liu X; Tan Q; Wen J; Wang X; Yang G; Li Y; Lu M; Ye W; Si A; Ma S; Ding T; Sun L; Liu F; Zhang M; Jiang T; Gao W
J Transl Med; 2023 Aug; 21(1):572. PubMed ID: 37626430
[TBL] [Abstract][Full Text] [Related]
2. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
3. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
Wang C; Gao W; Feng M; Pastan I; Ho M
Oncotarget; 2017 May; 8(20):32450-32460. PubMed ID: 27419635
[TBL] [Abstract][Full Text] [Related]
4. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
5. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
6. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
8. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
9. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
10. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.
Goyal A; Batra JK
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):247-54. PubMed ID: 10620501
[TBL] [Abstract][Full Text] [Related]
12. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
13. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
[TBL] [Abstract][Full Text] [Related]
14. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
15. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
17. A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker.
Hashemi Yeganeh H; Heiat M; Alavian SM; Rezaei E
Protein J; 2022 Oct; 41(4-5):527-542. PubMed ID: 36001255
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
Hamamichi S; Fukuhara T; Hattori N
Toxins (Basel); 2020 Oct; 12(10):. PubMed ID: 33076544
[TBL] [Abstract][Full Text] [Related]
19. Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29.
Duke-Cohan JS; Morimoto C; Schlossman SF
Transplantation; 1993 Nov; 56(5):1188-96. PubMed ID: 7504344
[TBL] [Abstract][Full Text] [Related]
20. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
